Income statement

Sales $2,200,000$

C$.$O$.$G$.$S $1,100,000$

Gross profit $1,100,000$

Depreciation $42,000$

SG&A $550,000$

Other Operating Expense $22,000$

Operating income $486,000$

Other Income $540,000$

Interest Income $240,000$

EBIT $1,266,000$

Interest Expense $240,000$

EBT $1,026,000$

Tax Expense $359,100$

Profit$/$Loss $666,900$

E$.$P$.$S $0\mathrm{.}667$

D$.$P$.$S $0\mathrm{.}233$

Balance Sheet

Assets

Cash $130,000$

Marketable securities $150,000$

Accounts Receivable $440,000$

post dated checks $220,000$

Inventory $1,100,000$

Total Current Assets $2,040,000$

PP&E $2,100,000$

Long$-$Term investments $6,000,000$

Land $2,000,000$

Total Long Term Assets $10,100,000$

Total Assets $12,140,000$

Liabilities

Accounts Payable $440,000$

Due to banks $680,000$

Accrued long$-$term debt $320,000$

Total Current Liabilities $1,440,000$

Long$-$Term loans $3,000,000$

Deferred Taxes $50,000$

Other Long$-$term Liabilities $150,000$

Total Long$-$Term Liabilities $3,200,000$

Total Liabilities $4,640,000$

Shareholders' Equity

Paid in Capital $5,000,000$

Retained Earnings $2,500,000$

Total Shareholders' Equity $7,500,000$

Total Liability and Equity $12,140,000$

Note: Use the information provided by XYZ Pharmaceuticals LLC in the $2024$ financial statements above to calculate the following financial ratios:

Market value ratio

Formula

Price$-$earning ratio Price per share $/$Earning per share

PEG ratio Price $-$earning ratio$/$Earning growth rate

Price$-$sales ratio Price per share $/$ Sales per share

Market$-$to$-$book$-$ratio Market value per share $/$ Book value per share

Tobins Q ration Market value of asset $/$ Replacement cost of asset